HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder Nabs U.S. Skin-Care Share With Strong Innovation, Advertising

This article was originally published in The Rose Sheet

Executive Summary

The Estee Lauder Companies will continue to increase advertising, which along with winning innovations helped grow skin-care sales 9% to roughly $1.02 billion in the company’s fiscal 2012 third quarter. Lauder’s performance in the U.S. skin-care market was particularly strong, the firm notes.

You may also be interested in...



Clinique, Dove Named “Top Risers” In BrandZ Report

More than half of the top 100 global brands identified in Millward Brown’s “BrandZ” report lost value this year compared with the prior year, a trend of magnitude not seen since “the depths of the 2009 global recession,” firm says. Nevertheless, “brand power” has not diminished, and there were some standout successes, including the Estee Lauder Companies’ Clinique and Unilever’s Dove.

FDA Strengthens Sunscreen Testing And Label Requirements

As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.

Estee Lauder Uncloaks Four-Year Plan For Slashing Costs, Growing Core Biz

The Estee Lauder Companies is implementing a four-year strategy to optimize its core strengths and cut costs by up to $550 million, the firm announced Feb. 5 in tandem with second-quarter sales, which declined 6 percent compared with the prior year, excluding the impact of foreign exchange

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel